Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam

Abstract

1. Cabotegravir (CAB; GSK1265744) is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

2. This work investigated if CAB was a substrate for efflux transporters, the potential for CAB to interact with drug-metabolizing enzymes and transporters to cause clinical drug interactions, and the effect of CAB on the pharmacokinetics of midazolam, a CYP3A4 probe substrate, in humans.

3. CAB is a substrate for Pgp and BCRP; however, its high intrinsic membrane permeability limits the impact of these transporters on its intestinal absorption.

4. At clinically relevant concentrations, CAB did not inhibit or induce any of the CYP or UGT enzymes evaluated in vitro and had no effect on the clinical pharmacokinetics of midazolam.

5. CAB is an inhibitor of OAT1 (IC₅₀ 0.81 µM) and OAT3 (IC₅₀ 0.41 µM) but did not or only weakly inhibited Pgp, BCRP, MRP2, MRP4, MATE1, MATE2-K, OATP1B1, OATP1B3, OCT1, OCT2 or BSEP.

6. Based on regulatory guidelines and quantitative extrapolations, CAB has a low propensity to cause clinically significant drug interactions, except for coadministration with OAT1 or OAT3 substrates.

• BCRP
• Cytochrome P450
• drug metabolism
• infections disease
• OAT
• P-glycoprotein
• transporters

Acknowledgements

The authors wish to thank Glenn Tabolt, Marta Johnson, Cory Watson, Phil Clark for their technical support and colleagues at GlaxoSmithKline who encouraged and supported this study.

Declaration of interest

These studies were funded by GlaxoSmithKline on behalf of ViiV Healthcare. All authors were employees of GlaxoSmithKline, Inc at the time of this work.

Supplementary Material Available online

Supplementary Tables 1-5